צפוויט פורטה תרחיף 이스라엘 - 히브리어 - Ministry of Health

צפוויט פורטה תרחיף

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - אבקה להכנת תרחיף - cefalexin as monohydrate 250 mg / 5 ml - cefalexin - cefalexin - antibiotic for the treatment of infections caused by micro-organisms sensitive to cephalexin.

צפוויט 250 이스라엘 - 히브리어 - Ministry of Health

צפוויט 250

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - קפסולות - cefalexin as monohydrate 250 mg - cefalexin - cefalexin - antibiotic for the treatment of infections caused by micro-organisms sensitive to cephalexin.

צפוויט פורטה 500 이스라엘 - 히브리어 - Ministry of Health

צפוויט פורטה 500

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - קפסולות - cefalexin as monohydrate 500 mg - cefalexin - cefalexin - treatment of infections caused by cephalexin susceptible microorganisms.

טסיגנה 200 מג 이스라엘 - 히브리어 - Ministry of Health

טסיגנה 200 מג

novartis israel ltd - nilotinib as monohydrate - קפסולות - nilotinib as monohydrate 200 mg - nilotinib - nilotinib - treatment of philadelphia chromosome positive chronic myeloid leukaemia (ph+ cml) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib.treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

טסיגנה 150 מג 이스라엘 - 히브리어 - Ministry of Health

טסיגנה 150 מג

novartis israel ltd - nilotinib as hydrochloride monohydrate - קפסולות - nilotinib as hydrochloride monohydrate 150 mg - nilotinib - nilotinib - treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

אלנדרונט טבע 10 מג 이스라엘 - 히브리어 - Ministry of Health

אלנדרונט טבע 10 מג

teva pharmaceutical industries ltd, israel - alendronic acid as monohydrate - טבליה - alendronic acid as monohydrate 10 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip, wrist and spine (vertebral compression fractures).for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women. for the treatment to increase bone mass in men with osteoporosis.

טבענט 이스라엘 - 히브리어 - Ministry of Health

טבענט

teva pharmaceutical industries ltd, israel - alendronic acid as monohydrate - טבליה - alendronic acid as monohydrate 10 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip, wrist and spine (vertebral compression fractures).for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women. for the treatment to increase bone mass in men with osteoporosis.

דואודופה 이스라엘 - 히브리어 - Ministry of Health

דואודופה

abbvie biopharmaceuticals ltd, israel - carbidopa as monohydrate; levodopa - ג'ל - levodopa 20 mg/ml; carbidopa as monohydrate 5 mg/ml - levodopa - levodopa - treatment of advanced levodopa-responsive parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of parkinson medicinal products have not given satisfactory results. a positive test of the clinical response to duodopa administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.

סטאלבו 7518.75200 מג 이스라엘 - 히브리어 - Ministry of Health

סטאלבו 7518.75200 מג

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - טבליות מצופות פילם - carbidopa as monohydrate 18.75 mg; entacapone 200 mg; levodopa 75 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.

סטאלבו 12531.25200 מג 이스라엘 - 히브리어 - Ministry of Health

סטאלבו 12531.25200 מג

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - טבליות מצופות פילם - levodopa 125 mg; entacapone 200 mg; carbidopa as monohydrate 31.25 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.